InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award

Recognized for Successful Introduction of New and Innovative Products, with Emphasis on Quality and Customer Value

Jul 07, 2015, 08:00 ET from InspireMD, Inc.

BOSTON, July 7, 2015 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems ("EPS"), today announced that its MGuard Prime Embolic Protection System integrated with MicroNet has received the Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award.  Through active market research efforts, Frost & Sullivan's global team of analysts and consultants recognize the successful introduction of new and innovative products, with emphasis on quality and customer value.

Frost & Sullivan Senior Research Analyst Parthasarathy Raghava stated, "While significant improvements in clinical outcomes of percutaneous coronary interventions have been achieved with the use of coronary stents, distal embolization remains a major complication, resulting in poorer functional recovery and adverse outcomes.  However, our market research activities noted that InspireMD's MGuard Primewith MicroNet addresses this challenge with its innovative design to trap and seal thrombus and plaque against the vessel wall, helping prevent distal embolization, while optimizing flow and ensuring excellent deliverability.  We are pleased to confer this Innovation Award on InspireMD."

MGuard Prime™ is a Cobalt Chromium stent wrapped in MicroNet™. MicroNet™ is a bio-stable mesh woven from a single strand of 20 micrometers Polyethylene Terephthalate.

Alan Milinazzo, CEO of InspireMD commented, "We are honored to receive the Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award, supporting our efforts to develop and commercialize embolic protection stent systems that improve patient outcomes by leveraging our proprietary MicroNet technology."

"We look forward to further enhancements to our coronary platform, including strategic partnerships in the development of a drug eluting stent system."  Mr. Milinazzo continued, "We are also in active development of new applications for our MicroNet technology, in addition to MGuardand our carotid system, CGuard, bringing innovation to treatment programs in the neurovascular and peripheral markets."

For more information about InspireMD and the Frost & Sullivan New Product Innovation Award, or The Coronary Stent Industry Research Report, visit www.inspiremd.com/en/investors/investor-relations/.

About Frost & Sullivan

Frost & Sullivan, founded in 1961, has more than 40 global offices with more than 1,800 industry consultants, market research analysts, technology analysts and economists. It is a growth partnership company focused on helping clients achieve transformational growth as they work through an economic environment dominated by accelerating change, increasing risk and the powerful disruptive impact of the conversion of new business models, disruptive technologies and Mega Trends on their industry.

Frost & Sullivan is a world leader in growth consulting and the integrated areas of technology research, market research, Mega Trends, economic research, best practices, training, customer research, competitive intelligence, and corporate strategy. For more information, visit www.frost.com.

About MGuard Prime EPS

MGuard Prime EPS, integrated with MicroNet™, is designed to trap and seal thrombus and ruptured plaque, preventing distal embolization. While offering superior performance relative to standard stents in STEMI patients with regard to ST segment resolution, MGuard Prime™ requires no change in current physician practice – an important factor in time-critical settings.

About CGuard EPS

The proprietary CGuard Embolic Prevention System (EPS) uses the same MicroNet technology featured on the MGuard and MGuard Prime coronary Embolic Protection Systems.  The CGuard™ EPS is designed to prevent peri-procedural and late embolization by trapping potential emboli against the arterial wall while maintaining excellent perfusion to the external carotid artery and branch vessels.

MGuard EPS and CGuard EPS are CE Marked and are not approved for sale in the U.S. by the U.S. Food and Drug Administration at this time.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MGuard™ with MicroNet technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this MicroNet™ technology in coronary, carotid (CGuard), neurovascular, and peripheral artery procedures.  InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

Forward-looking Statements:

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:
InspireMD, Inc.
Craig Shore
Chief Financial Officer
Phone: 1-888-776-6804 FREE
Email: craigs@inspiremd.com

PCG Advisory
Vivian Cervantes
Investor Relations
Phone:  (212) 554-5482

SOURCE InspireMD, Inc.



RELATED LINKS

http://www.inspiremd.com